The most common types of cancer are breast, lung, colon, rectum, and prostate. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence.
Radiopharmaceutical theranostics have promising potential in cancer therapy. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44Sc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 110In/111In, 124I/131I, 152Tb/161Tb, 152Tb/149Tb, 68Ga/177Lu, and 90Y/177Lu. 123I/131I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer.
Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. 89Zr- and 177Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for positron emission tomography (PET) imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for TRT and PET imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall market growth.
The Europe radiopharmaceutical theranostics market is segmented into the Germany, UK, France, Spain, Italy, and the Rest of Europe. Germany is expected to be among the largest contributors to the radiopharmaceutical theranostics market. The market growth in this region is due to the increasing incidences of chronic diseases such as cancer, diabetes, heart diseases, presence of supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies.
Europe Radiopharmaceutical Theranostics Market Segmentation
The Europe radiopharmaceutical theranostics market is segmented into product type, radioisotype, source, application, indication, end user, and country. Based on product type, the Europe radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The PET tracers segment held the largest market share in 2022.
Based on radioisotype, the Europe radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the Europe radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the Europe radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.
Based on indication, the Europe radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the Europe radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.
Based on country, the Europe radiopharmaceutical theranostics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe radiopharmaceutical theranostics market share in 2022.
Bayer AG, GE Healthcare Technologies Inc., Curium, Lantheus Medical Imaging, Inc., Telix Pharmaceuticals Ltd., Cardinal Health Inc., Advanced Accelerator Applications S.A, and Theragnostics are among the leading companies operating in the Europe radiopharmaceutical theranostics market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 462.25 Million |
| Market Size by 2028 | US$ 853.61 Million |
| CAGR (2022 - 2028) | 10.8% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Radiopharmaceutical Theranostics Market is valued at US$ 462.25 Million in 2022, it is projected to reach US$ 853.61 Million by 2028.
As per our report Europe Radiopharmaceutical Theranostics Market, the market size is valued at US$ 462.25 Million in 2022, projecting it to reach US$ 853.61 Million by 2028. This translates to a CAGR of approximately 10.8% during the forecast period.
The Europe Radiopharmaceutical Theranostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Radiopharmaceutical Theranostics Market report:
The Europe Radiopharmaceutical Theranostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Radiopharmaceutical Theranostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Radiopharmaceutical Theranostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Radiopharmaceutical Theranostics Market
